Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Abstract
During the past 10 years, several new basal insulin analogs have been developed. There has been for 3 years controversy on the potential increased risk for cancer with insulin glargine, which ceased with the publication of the ORIGIN trial in 2012. In insulin-treated persons with type 2 diabetes, it is usual to recommend that plasma insulin concentrations remain within a 50-200 pmol/L range in order to avoid overinsulinization, a potential...
Paper Details
Title
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Published Date
Dec 1, 2013
Journal
Volume
39
Issue
6
Pages
468 - 476
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History